KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Description

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Conditions

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Condition
Myelofibrosis
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology, Birmingham, Alabama, United States, 35233

Whittier

The Oncology Institute of Hope, Whittier, California, United States, 90603

Lake City

Lake City Cancer Center, Lake City, Florida, United States, 32024

Urbana

Carle Cancer Center, Urbana, Illinois, United States, 61801

Fort Lee

Columbia University Medical Center, Fort Lee, New Jersey, United States, 07024

New York

Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)
  • * ECOG ≤ 2
  • * Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment
  • * Cohort 3: patients who are intolerant to JAK inhibitor treatment
  • * Prior treatment with MDM2 inhibitors or p53-directed therapies
  • * Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor
  • * Prior splenectomy
  • * Splenic irradiation within 3 months prior to the first dose of study treatment
  • * Clinically significant thrombosis within 3 months of screening
  • * Grade 2 or higher QTc prolongation

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kartos Therapeutics, Inc.,

Study Record Dates

2025-07-24